371 related articles for article (PubMed ID: 26864108)
21. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
[TBL] [Abstract][Full Text] [Related]
22. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
23. Yeast Surface Display and Cell Sorting of Antigen-Binding Fc Fragments.
Sádio F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Methods Mol Biol; 2019; 1923():287-308. PubMed ID: 30737746
[TBL] [Abstract][Full Text] [Related]
24. When binding is enough: nonactivating antibody formats.
Labrijn AF; Aalberse RC; Schuurman J
Curr Opin Immunol; 2008 Aug; 20(4):479-85. PubMed ID: 18577454
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
Skegro D; Stutz C; Ollier R; Svensson E; Wassmann P; Bourquin F; Monney T; Gn S; Blein S
J Biol Chem; 2017 Jun; 292(23):9745-9759. PubMed ID: 28450393
[TBL] [Abstract][Full Text] [Related]
26. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
27. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
28. A variant human IgG1-Fc mediates improved ADCC.
Stewart R; Thom G; Levens M; Güler-Gane G; Holgate R; Rudd PM; Webster C; Jermutus L; Lund J
Protein Eng Des Sel; 2011 Sep; 24(9):671-8. PubMed ID: 21596686
[TBL] [Abstract][Full Text] [Related]
29. Selection of High-Affinity Heterodimeric Antigen-Binding Fc Fragments from a Large Yeast Display Library.
Benedetti F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Methods Mol Biol; 2023; 2681():131-159. PubMed ID: 37405647
[TBL] [Abstract][Full Text] [Related]
30. Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding.
Orlandi C; Deredge D; Ray K; Gohain N; Tolbert W; DeVico AL; Wintrode P; Pazgier M; Lewis GK
Structure; 2020 May; 28(5):516-527.e5. PubMed ID: 32209433
[TBL] [Abstract][Full Text] [Related]
31. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.
Fonseca MHG; Furtado GP; Bezerra MRL; Pontes LQ; Fernandes CFC
Int J Biol Macromol; 2018 Nov; 119():306-311. PubMed ID: 30041038
[TBL] [Abstract][Full Text] [Related]
32. Construction of pH-sensitive Her2-binding IgG1-Fc by directed evolution.
Traxlmayr MW; Lobner E; Hasenhindl C; Stadlmayr G; Oostenbrink C; Rüker F; Obinger C
Biotechnol J; 2014 Aug; 9(8):1013-22. PubMed ID: 24964247
[TBL] [Abstract][Full Text] [Related]
33. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
34. Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding.
Lu X; Machiesky LA; De Mel N; Du Q; Xu W; Washabaugh M; Jiang XR; Wang J
Sci Rep; 2020 Jan; 10(1):383. PubMed ID: 31941950
[TBL] [Abstract][Full Text] [Related]
35. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
36. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
37. B Cell-Based Seamless Engineering of Antibody Fc Domains.
Hashimoto K; Kurosawa K; Murayama A; Seo H; Ohta K
PLoS One; 2016; 11(12):e0167232. PubMed ID: 27907066
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment.
Zeng F; Yang C; Gao X; Li X; Zhang Z; Gong R
J Biol Chem; 2018 Dec; 293(49):19127-19135. PubMed ID: 30327432
[TBL] [Abstract][Full Text] [Related]
39. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
40. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
